Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript November 13, 2023 Astria Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.63 EPS, expectations were $-0.51. Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode. [Operator Instructions] As a […]
Operator: Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update. At this time, all attendees are in a listen-only mode.
Glenmark's subsidiary Ichnos Sciences enters into licensing agreement with Astria Therapeutics for its monoclonal antibody portfolio financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.
With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company s prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.
Glenmark subsidiary Ichnos will receive up to $320 million in upfront, development, regulatory and sales milestone payments in addition to up to low double-digit royalties